Cargando…

Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials

The association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and various cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to explore whether use of SGLT2is is significantly associated with the occurrences of 80 types of cardiovascular diseases and 55...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Dao-Gen, Qiu, Mei, Duan, Xue-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350118/ https://www.ncbi.nlm.nih.gov/pubmed/34381370 http://dx.doi.org/10.3389/fphar.2021.724405

Ejemplares similares

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
por: Xie, Lingxiang, et al.
Publicado: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
por: Yang, Shiwen, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
por: Qiu, Mei, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Zhang, Wan-Tong, et al.
Publicado: (2021)

Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials
por: Duan, Xue-Yan, et al.
Publicado: (2021)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
por: Demin, Oleg, et al.
Publicado: (2014)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Pahud de Mortanges, Aurélie, et al.
Publicado: (2021)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
por: Lin, Hui, et al.
Publicado: (2021)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Role of Neuromuscular Blocking Agents in Acute Respiratory Distress Syndrome: An Updated Meta-Analysis of Randomized Controlled Trials
por: Wei, Xue-biao, et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial
por: Zhao, Li-Min, et al.
Publicado: (2021)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy via the JNK and p38 Pathway
por: Lin, Na, et al.
Publicado: (2021)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
por: Zhou, Xiang, et al.
Publicado: (2021)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Epidemiological associations between iron and cardiovascular disease and diabetes
por: Basuli, Debargha, et al.
Publicado: (2014)

RNA Methylations in Cardiovascular Diseases, Molecular Structure, Biological Functions and Regulatory Roles in Cardiovascular Diseases
por: Zhou, Wanwan, et al.
Publicado: (2021)

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Marafini, Irene, et al.
Publicado: (2021)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
por: Xing, Yu-jie, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis
por: Zou, Cai-Yan, et al.
Publicado: (2019)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Cardiovascular Alterations and Management of Patients With White Coat Hypertension: A Meta-Analysis
por: Xiang, Huaqiang, et al.
Publicado: (2020)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

P2X7 Receptor–Mediated Inflammation in Cardiovascular Disease
por: Zhou, Junteng, et al.
Publicado: (2021)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
por: Gu, Yunpeng, et al.
Publicado: (2023)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Chen, Yuehong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kqim0o2sqg5uilcev9c8cejp9s